沙雷肽酶 Serrapeptase

INT-serrapeptase-001 3 個適應症被研究
C 2 D 1

適應症與證據等級

法規與權威立場 (L4)

L4a · US FDA
立場:cautious
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations.
來源 ↗
L4b · EU EFSA
立場:against
L4c · UK NHS
立場:against
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food.
來源 ↗
L4d · TW TFDA / 衛福部
立場:neutral
適應症:手術後及外傷後之消炎、副鼻腔炎、膀胱炎、副睪丸炎、智齒周圍炎、齒槽膿瘍之消炎、支氣管炎。
來源 ↗
L4e · WHO
立場:not_addressed

市場與行銷 (L10)

L10a · TW Market Channels
強效沙雷肽酶Serrapeptase(延遲釋放)
L10b · TW Legal Identity (TFDA)
以現在要求的臨床數據評估,並無足夠證據足以支持其療效
L10c · TW Community (PTT/Dcard/Mobile01)